325767
Lanthanum(III) carbonate hydrate
99.9% trace metals basis
Synonym(s):
Fosrenol, Lanthanum(3+) tricarbonate hydrate
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Linear Formula:
La2(CO3)3·xH2O
CAS Number:
Molecular Weight:
457.84 (anhydrous basis)
EC Number:
MDL number:
UNSPSC Code:
12352302
PubChem Substance ID:
NACRES:
NA.23
Assay:
99.9% trace metals basis
form:
powder
Recommended Products
Assay
99.9% trace metals basis
form
powder
composition
Degree of hydration, 2-5
reaction suitability
reagent type: catalyst
core: lanthanum
impurities
≤1500.0 ppm Trace Rare Earth Analysis
SMILES string
O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O
InChI
1S/3CH2O3.2La.H2O/c3*2-1(3)4;;;/h3*(H2,2,3,4);;;1H2/q;;;2*+3;/p-6
InChI key
AFCUGQOTNCVYSW-UHFFFAOYSA-H
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
nwg
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Reiko Inoue et al.
Clinical and experimental nephrology, 23(6), 859-864 (2019-03-02)
This study aims to describe the regional variance in prescriptions for chronic kidney disease (CKD) medications and to analyze regional characteristics to identify the sources of these differences by utilizing the National Database of Health Insurance Claims, which provides more
Atsushi Yaguchi et al.
PloS one, 12(7), e0180430-e0180430 (2017-07-14)
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them
Stefan P Schumacher et al.
Nephrology (Carlton, Vic.), 24(2), 221-226 (2018-02-27)
Hyperphosphataemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate
Olivier Phan et al.
BioMed research international, 2015, 515606-515606 (2015-07-30)
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service